Cigna Corporation
Get $10 bonus on your first $100 deposit for CI
Get $10 bonus on your first $100 deposit for CI
Cigna Corporation (CI) Stock Competitors & Peer Comparison
See (CI) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CI | $270.02 | +1.01% | 72.1B | 12.17 | $22.19 | +2.26% |
| UNH | $277.26 | +1.20% | 251.7B | 20.96 | $13.23 | +3.19% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| CVS | $73.49 | +1.38% | 93.5B | 52.87 | $1.39 | +3.62% |
| ELV | $300.74 | +0.75% | 66.4B | 11.93 | $25.20 | +2.28% |
| HUM | $177.85 | +0.51% | 21.4B | 18.07 | $9.84 | +1.99% |
| CNC | $35.10 | +3.39% | 17.3B | -2.59 | -$13.53 | N/A |
| MOH | $139.38 | +2.62% | 7.2B | 15.63 | $8.92 | N/A |
| ALHC | $18.76 | +5.10% | 3.8B | -170.55 | -$0.11 | N/A |
| OSCR | $11.92 | +1.62% | 3.1B | -7.05 | -$1.69 | N/A |
Stock Comparison
CI vs UNH Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, UNH has a market cap of 251.7B. Regarding current trading prices, CI is priced at $270.02, while UNH trades at $277.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas UNH's P/E ratio is 20.96. In terms of profitability, CI's ROE is +0.15%, compared to UNH's ROE of +0.13%. Regarding short-term risk, CI is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check UNH's competition here
CI vs ANTM Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, CI is priced at $270.02, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas ANTM's P/E ratio is 18.99. In terms of profitability, CI's ROE is +0.15%, compared to ANTM's ROE of +0.13%. Regarding short-term risk, CI is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check ANTM's competition here
CI vs CVS Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, CVS has a market cap of 93.5B. Regarding current trading prices, CI is priced at $270.02, while CVS trades at $73.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas CVS's P/E ratio is 52.87. In terms of profitability, CI's ROE is +0.15%, compared to CVS's ROE of +0.02%. Regarding short-term risk, CI is less volatile compared to CVS. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CVS's competition here
CI vs ELV Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, ELV has a market cap of 66.4B. Regarding current trading prices, CI is priced at $270.02, while ELV trades at $300.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas ELV's P/E ratio is 11.93. In terms of profitability, CI's ROE is +0.15%, compared to ELV's ROE of +0.13%. Regarding short-term risk, CI is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check ELV's competition here
CI vs HUM Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, HUM has a market cap of 21.4B. Regarding current trading prices, CI is priced at $270.02, while HUM trades at $177.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas HUM's P/E ratio is 18.07. In terms of profitability, CI's ROE is +0.15%, compared to HUM's ROE of +0.07%. Regarding short-term risk, CI is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check HUM's competition here
CI vs CNC Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, CNC has a market cap of 17.3B. Regarding current trading prices, CI is priced at $270.02, while CNC trades at $35.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas CNC's P/E ratio is -2.59. In terms of profitability, CI's ROE is +0.15%, compared to CNC's ROE of -0.28%. Regarding short-term risk, CI is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CNC's competition here
CI vs MOH Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, MOH has a market cap of 7.2B. Regarding current trading prices, CI is priced at $270.02, while MOH trades at $139.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas MOH's P/E ratio is 15.63. In terms of profitability, CI's ROE is +0.15%, compared to MOH's ROE of +0.11%. Regarding short-term risk, CI is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check MOH's competition here
CI vs ALHC Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, ALHC has a market cap of 3.8B. Regarding current trading prices, CI is priced at $270.02, while ALHC trades at $18.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas ALHC's P/E ratio is -170.55. In terms of profitability, CI's ROE is +0.15%, compared to ALHC's ROE of -0.00%. Regarding short-term risk, CI is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check ALHC's competition here
CI vs OSCR Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, OSCR has a market cap of 3.1B. Regarding current trading prices, CI is priced at $270.02, while OSCR trades at $11.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas OSCR's P/E ratio is -7.05. In terms of profitability, CI's ROE is +0.15%, compared to OSCR's ROE of -0.39%. Regarding short-term risk, CI is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check OSCR's competition here
CI vs CLOV Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, CLOV has a market cap of 880.6M. Regarding current trading prices, CI is priced at $270.02, while CLOV trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas CLOV's P/E ratio is -10.12. In terms of profitability, CI's ROE is +0.15%, compared to CLOV's ROE of -0.26%. Regarding short-term risk, CI is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CLOV's competition here
CI vs BHG Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, CI is priced at $270.02, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas BHG's P/E ratio is -0.12. In terms of profitability, CI's ROE is +0.15%, compared to BHG's ROE of -0.70%. Regarding short-term risk, CI is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check BHG's competition here
CI vs CABR Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, CABR has a market cap of 16.4M. Regarding current trading prices, CI is priced at $270.02, while CABR trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas CABR's P/E ratio is -2.41. In terms of profitability, CI's ROE is +0.15%, compared to CABR's ROE of N/A. Regarding short-term risk, CI is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CABR's competition here
CI vs BMGL Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, BMGL has a market cap of 11.2M. Regarding current trading prices, CI is priced at $270.02, while BMGL trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas BMGL's P/E ratio is -1.35. In terms of profitability, CI's ROE is +0.15%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, CI is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check BMGL's competition here
CI vs MRAI Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, MRAI has a market cap of 5.7M. Regarding current trading prices, CI is priced at $270.02, while MRAI trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas MRAI's P/E ratio is -0.11. In terms of profitability, CI's ROE is +0.15%, compared to MRAI's ROE of +0.52%. Regarding short-term risk, CI is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check MRAI's competition here
CI vs NIVF Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, NIVF has a market cap of 1.2M. Regarding current trading prices, CI is priced at $270.02, while NIVF trades at $2.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas NIVF's P/E ratio is 0.06. In terms of profitability, CI's ROE is +0.15%, compared to NIVF's ROE of +1.17%. Regarding short-term risk, CI is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check NIVF's competition here
CI vs MGLN Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, CI is priced at $270.02, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas MGLN's P/E ratio is 8.49. In terms of profitability, CI's ROE is +0.15%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, CI is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check MGLN's competition here
CI vs AET Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, AET has a market cap of 0. Regarding current trading prices, CI is priced at $270.02, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas AET's P/E ratio is N/A. In terms of profitability, CI's ROE is +0.15%, compared to AET's ROE of +0.11%. Regarding short-term risk, CI is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check AET's competition here
CI vs UAM Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, UAM has a market cap of 0. Regarding current trading prices, CI is priced at $270.02, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas UAM's P/E ratio is N/A. In terms of profitability, CI's ROE is +0.15%, compared to UAM's ROE of +0.17%. Regarding short-term risk, CI is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check UAM's competition here
CI vs GTS Comparison April 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 72.1B. In comparison, GTS has a market cap of 0. Regarding current trading prices, CI is priced at $270.02, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 12.17, whereas GTS's P/E ratio is 10.41. In terms of profitability, CI's ROE is +0.15%, compared to GTS's ROE of +0.07%. Regarding short-term risk, CI is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check GTS's competition here